Timo Vesikari1, Nicholas Brodszki, Pierre van Damme, Javier Diez-Domingo, Giancarlo Icardi, Lone Kjeld Petersen, Clément Tran, Stéphane Thomas, Alain Luxembourg, Martine Baudin. 1. From the *Vaccine Research Centre, University of Tampere, Tampere, Finland; †Children's Hospital, Lund University, Lund, Sweden; ‡Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium; §Vaccine Research Department, FISABIO-Public Health, Valencia, Spain; ¶Department of Health Sciences, University of Genoa, IRCSS AOU San Martino-IST, Genoa, Italy; ‖Department of Gynaecology and Obstetrics, Aarhus University Hospital, Skejby, Denmark; **Sanofi Pasteur MSD, Lyon, France; and ††Merck & Co., Inc., Whitehouse Station, NJ.
Abstract
BACKGROUND: A 9-valent human papillomavirus (9vHPV) vaccine has been developed to prevent infections and diseases related to HPV 6/11/16/18 [as per the licensed quadrivalent HPV (qHPV) vaccine], as well as 5 additional oncogenic HPV types (HPV 31/33/45/52/58). Compared with the qHPV vaccine, the 9vHPV vaccine potentially increases the coverage of protection from 70% to 90% of cervical cancers. We compared the immunogenicity and safety of the 9vHPV vaccine versus the qHPV vaccine in 9-15-year-old girls. METHODS:Participants (n = 600) were randomized to receive 9vHPV or qHPV vaccines on day 1, month 2 and month 6. Serology testing was performed on day 1 and month 7. HPV type-specific antibody titers (anti-HPV 6/11/16/18/31/33/45/52/58) were determined by competitive Luminex immunoassay and expressed as geometric mean titers and seroconversion rates. Vaccine safety was also assessed. RESULTS: The HPV 6/11/16/18 immune responses elicited by the 9vHPV vaccine were comparable with those elicited by the qHPV vaccine. All participants (except 1 for HPV 45) receiving the 9vHPV vaccine seroconverted for HPV 31/33/45/52/58. The 9vHPV and qHPV vaccines showed comparable safety profiles, although the incidence of injection-site swelling was higher in the 9vHPV vaccine group. CONCLUSIONS: In addition to immune responses to HPV 31/33/45/52/58, a 3-dose regimen of the 9vHPV vaccine elicited a similar immune response to HPV 6/11/16/18 when compared with the qHPV vaccine in girls aged 9-15 years. The safety profile was also similar for the 2 vaccines.
RCT Entities:
BACKGROUND: A 9-valent human papillomavirus (9vHPV) vaccine has been developed to prevent infections and diseases related to HPV 6/11/16/18 [as per the licensed quadrivalent HPV (qHPV) vaccine], as well as 5 additional oncogenic HPV types (HPV 31/33/45/52/58). Compared with the qHPV vaccine, the 9vHPV vaccine potentially increases the coverage of protection from 70% to 90% of cervical cancers. We compared the immunogenicity and safety of the 9vHPV vaccine versus the qHPV vaccine in 9-15-year-old girls. METHODS:Participants (n = 600) were randomized to receive 9vHPV or qHPV vaccines on day 1, month 2 and month 6. Serology testing was performed on day 1 and month 7. HPV type-specific antibody titers (anti-HPV 6/11/16/18/31/33/45/52/58) were determined by competitive Luminex immunoassay and expressed as geometric mean titers and seroconversion rates. Vaccine safety was also assessed. RESULTS: The HPV 6/11/16/18 immune responses elicited by the 9vHPV vaccine were comparable with those elicited by the qHPV vaccine. All participants (except 1 for HPV 45) receiving the 9vHPV vaccine seroconverted for HPV 31/33/45/52/58. The 9vHPV and qHPV vaccines showed comparable safety profiles, although the incidence of injection-site swelling was higher in the 9vHPV vaccine group. CONCLUSIONS: In addition to immune responses to HPV 31/33/45/52/58, a 3-dose regimen of the 9vHPV vaccine elicited a similar immune response to HPV 6/11/16/18 when compared with the qHPV vaccine in girls aged 9-15 years. The safety profile was also similar for the 2 vaccines.
Authors: Debbie Saslow; Kimberly S Andrews; Deana Manassaram-Baptiste; Lacey Loomer; Kristina E Lam; Marcie Fisher-Borne; Robert A Smith; Elizabeth T H Fontham Journal: CA Cancer J Clin Date: 2016-07-19 Impact factor: 508.702
Authors: Rosie T Jiang; Christina Schellenbacher; Bryce Chackerian; Richard B S Roden Journal: Expert Rev Vaccines Date: 2016-03-10 Impact factor: 5.217
Authors: Nicolas F Schlecht; Angela Diaz; Viswanathan Shankar; Arnold H Szporn; Maoxin Wu; Anne Nucci-Sack; Ken Peake; Howard D Strickler; Robert D Burk Journal: J Infect Dis Date: 2016-10-12 Impact factor: 5.226
Authors: Alex Vorsters; Marc Arbyn; Marc Baay; Xavier Bosch; Silvia de Sanjosé; Sharon Hanley; Emilie Karafillakis; Pier Luigi Lopalco; Kevin G Pollock; Joanne Yarwood; Pierre Van Damme Journal: Papillomavirus Res Date: 2017-07-20
Authors: Mary Roz Timbang; Michael W Sim; Arnaud F Bewley; D Gregory Farwell; Avinash Mantravadi; Michael G Moore Journal: Hum Vaccin Immunother Date: 2019-05-07 Impact factor: 3.452
Authors: Jennifer C Spencer; Noel T Brewer; Justin G Trogdon; Morris Weinberger; Tamera Coyne-Beasley; Stephanie B Wheeler Journal: Pediatrics Date: 2020-11-16 Impact factor: 7.124